Blueprint
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2016.
Commission File Number: 000-53805
Intellipharmaceutics International
Inc.
(Translation of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x
] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the
submission in paper of a Form 6-K if submitted to furnish a report
or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules
of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is
not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form
6-K submission or other Commission filing on
EDGAR.
This
Report of Foreign Private Issuer on Form 6-K and the attached
exhibit 99.1 shall be incorporated by reference into the
Company’s effective Registration Statement on Form F-3, as
amended and supplemented (Registration Statement No. 333-196112),
filed with the Securities and Exchange Commission, from the date on
which this Report is filed, to the extent not superseded by
documents or reports subsequently filed or furnished by
Intellipharmaceutics International Inc. under the Securities Act of
1933 or the Securities Exchange Act of 1934.
Intellipharmaceutics
International Inc. (the “Registrant”) has instructed
American Stock Transfer & Trust Company, LLC
(“AST”) to send a notice (the “Notice”) to
holders of the Common Stock Purchase Warrants issued by the
Registrant on or after June 2, 2016 in connection with that certain
Underwriting Agreement between the Registrant and Dawson James
Securities, Inc., dated May 27, 2016 (the “Warrants”).
The Notice relates to the appointment of AST as warrant agent for
the purpose of having AST act on behalf of the Registrant in
connection with the registration, transfer, exchange and exercise
of the Warrants. (AST is not acting as warrant agent in respect of
any other warrants previously issued by the Registrant.) A copy of
the form of Notice to be sent to the holders of the Warrants is
attached hereto as Exhibit 99.1 and incorporated by reference
herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
|
Intellipharmaceutics
International Inc.
(Registrant)
/s/
Domenic Della Penna
|
|
Date: October 6, 2016
|
|
Domenic Della Penna
Chief Financial Officer
|
EXHIBIT LIST
|
Exhibit
|
Description
|
|
99.1
|
Form of Notice to Warrant Holders
|